Healio’s Post

Europe’s medical market continues to see strong growth concentrated in key countries, with steady growth elsewhere, albeit often from a low base. Currently, 21 countries see patient treatment with medical cannabis; however, in most cases patient numbers are still very low, and the process for treatment can involve high costs and bureaucratic hurdles. Download the Global Cannabis Report: 4th Edition https://lnkd.in/eB38Qe6c

By now you may have heard about the rescheduling of cannabis, and the recognition of its medicinal qualities. If you have been wondering if you qualify for a cannabis medical card, the process is easier than it’s ever been. Follow this link for a detailed instructions: https://vist.ly/35826

Our latest edition of "The Cannabis Briefing" is here, featuring a Cansativa Expert Dialogue! 🎉 In this edition, we delve into the growth and regulation of Germany's medical cannabis industry. Our Managing Director and COO, Roland Schneller, shares insights into how we've navigated through challenges, embraced innovation, and maintained our commitment to quality and reliability. Roland also sheds light on the crucial factors driving success in the evolving landscape of medical cannabis. 🇩🇪 Read the German version here: https://lnkd.in/dxmsMuRY 🇬🇧 Read the English version here: https://lnkd.in/d-98PZWP If you're passionate about revolutionizing the cannabis industry, stay tuned for more updates and follow our briefings! Happy reading! #CannabisBriefing #MedicalCannabis #Newsletter #BusinessInsights #ExpertDialogue #StayInformed #WeEnableCannabis #Cansativa 📰🌿

It's an interesting time in Australia's medical cannabis landscape. Our complimentary short course, "History of Medical Cannabis," delves into the rich and complex journey of cannabis, from its ancient therapeutic use to its modern-day acceptance in healthcare. Gain a deeper understanding of cannabis in its historical context, the social attitudes that have shaped its status, and its impact in today's medical field. Enrol now at www.saged.com.au 🌿

Tilray Medical, a #division of Tilray Brands, Inc. ("Tilray") (#Nasdaq: TLRY; TSX: TLRY) and a #global #leader in #medical #cannabis, empowering the #therapeutic #alliance between #patients and #healthcare #practitioners to make #informed individualized #health #decisions, today announced a new Tilray-led #scientific #publication titled, Medical Cannabis for Patients Over Age 50: A Multi-Site, Prospective Study of Patterns of Use and Health Outcomes. The Medical Cannabis in Older Patients Study (“#MCOPS ”) is a #multisite, #prospective, #observational #study examining the #realworld #impact of #medical use on #patients over the #age of 50 and under the #guidance of a #healthcare #provider.

Rescheduling THC to Schedule III: The Potential Impact on the Cannabis Industry The possible rescheduling of THC from Schedule I to Schedule III represents a pivotal moment for the cannabis industry. Here, we discuss the many potential implications of such a change, focusing on the medical, economic, and societal aspects of the cannabis market. ➡️ Read the Stuck on Compliance blog to learn more: https://ow.ly/IKfQ50Qq2UG

I recently had the opportunity to pre-review this comprehensive report on the German medical cannabis market, with a specific focus on cannabis flower, and I must say that it stands out for its depth and detail. This report is unmatched in its thorough examination of the market and offers valuable insights. If you're looking for the most detailed and up-to-date analysis available, this is the report to rely on.

JUST RELEASED! Download Medical Cannabis: A Healio Guide for Clinicians to learn the latest evidence regarding the use of cannabis for several of the most common indications: https://bit.ly/3xoEXkF

JUST RELEASED! Download Medical Cannabis: A Healio Guide for Clinicians to learn the latest evidence regarding the use of cannabis for several of the most common indications: https://bit.ly/3xoEXkF

Most global medical cannabis products are dispensed to patients 12-18 months after the flower is harvested. Consequently the cannabinoid and terpene concentrations will be reduced, and so too will be the patient's therapeutic experience. Our freshness mission is to dispense to the first patients within 28 days from end of cure, for each small batch. We are not there yet, but we are relentlessly working with our entire supply chain to reach our goal. What do you think? Does fresh cannabis make a difference to patients' therapeutic experience?